©The Author(s) 2025.
World J Diabetes. Oct 15, 2025; 16(10): 111230
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.111230
Published online Oct 15, 2025. doi: 10.4239/wjd.v16.i10.111230
Table 3 Comparison of the efficacy outcomes in the automated insulin delivery vs the control arms at the end of the studies
| Outcome variables (continuous) | Type of the randomized trial | Number of study reports | Number of participants with outcome analyzed | Pooled effect size, mean differences (95%CI) | P value | I2 (%) | |
| Automated insulin delivery arm | Control arm | ||||||
| TAR > 10 mmol/L (%) | All | 5 | 294 | 186 | -19.48 (-27.14 to -11.82) | < 0.00001 | 73 |
| Crossover | 3 | 69 | 68 | -20.69 (-33.35 to -8.03) | 0.001 | 79 | |
| Parallel-group | 2 | 225 | 118 | -18.38 (-31.42 to -5.35) | 0.006 | 73 | |
| TAR > 13.9 mmol/L (%) | All | 4 | 268 | 160 | -8.33 (-12.89 to -3.77) | 0.0003 | 71 |
| Crossover | 2 | 43 | 42 | -8.05 (-17.70 to 1.61) | 0.10 | 79 | |
| Parallel-group | 2 | 225 | 118 | -11.71 (-23.51 to 0.08) | 0.05 | 73 | |
| TAR > 20 mmol/L (%) | Crossover | 2 | 52 | 51 | -4.39 (-6.79 to -1.98) | 0.0004 | 0 |
| TBR < 3.9 mmol/L (%) | All | 5 | 294 | 186 | -0.07 (-0.21 to 0.08) | 0.37 | 22 |
| Crossover | 3 | 69 | 68 | -0.17 (-0.42 to 0.09) | 0.20 | 32 | |
| Parallel-group | 2 | 225 | 118 | 0.00 (-0.09 to 0.09) | 0.99 | 0 | |
| TBR < 3 mmol/L (%) | All | 5 | 294 | 186 | -0.01 (-0.03 to 0.02) | 0.57 | 39 |
| Crossover | 3 | 69 | 68 | -0.03 (-0.09 to 0.03) | 0.32 | 69 | |
| Parallel-group | 2 | 225 | 118 | 0.00 (-0.02 to 0.02) | 1.00 | 0 | |
| Mean SG (mmol/L) | All | 5 | 451 | 335 | -1.21 (-1.93 to -0.49) | 0.001 | 83 |
| Crossover | 3 | 69 | 68 | -1.82 (-3.34 to -0.30) | 0.02 | 84 | |
| Parallel-group | 2 | 382 | 267 | -0.66 (-1.34 to 0.03) | 0.06 | 81 | |
| SD of SG (mmol/L) | Crossover | 3 | 69 | 68 | -0.40 (-0.64 to -0.15) | 0.001 | 0 |
| Coefficient of variation of glucose (%) | All | 5 | 294 | 186 | 0.91 (-1.04 to 2.87) | 0.36 | 68 |
| Crossover | 3 | 69 | 68 | 0.51 (-2.90 to 3.93) | 0.77 | 77 | |
| Parallel-group | 2 | 225 | 118 | 1.35 (-0.27 to 2.97) | 0.10 | 17 | |
| Time using continuous glucose monitoring sensor (%) | Crossover | 3 | 69 | 68 | 2.80 (1.55-4.05) | < 0.0001 | 13 |
| TDDI (U) | All | 6 | 458 | 344 | -5.45 (-22.20 to 11.29) | 0.52 | 74 |
| Crossover | 3 | 69 | 68 | 13.24 (-11.64 to 38.12) | 0.30 | 65 | |
| Parallel-group | 3 | 389 | 276 | -21.07 (-30.15 to -11.99) | < 0.00001 | 0 | |
| TDDI (U/kg) | All | 3 | 262 | 150 | -0.04 (-0.20 to 0.11) | 0.59 | 53 |
| Crossover | 2 | 52 | 51 | 0.06 (-0.20 to 0.32) | 0.67 | 50 | |
| Parallel-group | 1 | 210 | 99 | -0.13 (-0.24 to -0.02) | 0.02 | Not reported | |
- Citation: Kamrul-Hasan ABM, Pappachan JM, Nagendra L, Akter N, Jena S, Dutta D, Nair S. Role of automated insulin delivery in managing insulin-treated outpatients with type 2 diabetes: A systematic review and meta-analysis. World J Diabetes 2025; 16(10): 111230
- URL: https://www.wjgnet.com/1948-9358/full/v16/i10/111230.htm
- DOI: https://dx.doi.org/10.4239/wjd.v16.i10.111230